8-K ·Filed Apr 13, 2026
8-K context-dependent: Items 8.01
Actionable Insight • Neutral
Monitor upcoming topline data from LUGANO/LUCIA trials in mid-2026 and COMO/CAPRI enrollment completion in 3Q 2026 for DME. The lack of new financial data suggests this is an informational update rather than a material event.
Final — all horizons settled through T+60d
EYPT ▲ +3.49% at T+60d
NEUTRAL call +3.49% · α vs SPY -5.04% · entry $14.34 → $14.84
T+1d
+2.02%
call +2.02% · α +1.25%
$14.63
settled 7mo ago
T+5d
-1.60%
call -1.60% · α -3.00%
$14.11
settled 6mo ago
T+20d
-2.51%
call -2.51% · α -8.81%
$13.98
settled 6mo ago
T+60d
+3.49%
call +3.49% · α -5.04%
$14.84
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
EyePoint, Inc. updated its investor presentation, highlighting positive clinical data for DURAVYU in wet AMD and DME, upcoming Phase 3 trial data, and a cash runway into Q4 2027. The filing is routine and does not contain new financial disclosures.
Key Facts
- Posted updated investor presentation on April 13, 2026
- DURAVYU Phase 3 trials in wet AMD and DME are ongoing
- Topline data for wet AMD trials expected mid-2026
- Full enrollment expected in DME trials in 3Q 2026
- Cash and investments support runway into Q4 2027
Financial Impact
No material financial impact disclosed in this filing
Risk Factors
- Clinical trial data may not meet expectations
- Regulatory approval timeline remains uncertain
- Cash runway depends on successful financing or commercialization
Market Snapshot
Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Investment Themes
Industrials & Manufacturing
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152852 |
| Document: eypt-ex99_1.htm | 0001193125-26-152852 |
| Document: 0001193125-26-152852-index-headers.html | 0001193125-26-152852 |
| Document: 0001193125-26-152852-index.html | 0001193125-26-152852 |
| Document: 0001193125-26-152852.txt | 0001193125-26-152852 |
17 reports for EYPT
60% Hit rate @ T+5 Went positive at some point 3 of 5 best @ T+5▲ +16.89%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3707 | ▲ +15.75% | ▲ +15.61% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | Press Release | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 7, 2026 19d ago | SC 13G/A | $3.32 $3.01 | ▼ −9.34% | ▼ −8.36% | $0.3700 (−88.86%) |
Sep 10, 2026 6w ago | 8-K | $4.25 $3.99 | ▼ −6.12% | ▼ −5.62% | $0.3700 (−91.29%) |
Aug 18, 2026 9w ago | Insider Buy | $6.30 $4.99 | ▼ −20.79% | ▼ −20.41% | $0.3700 (−94.13%) |
Aug 17, 2026 10w ago | 8-K | $4.87 $4.87 | · 0.00% | ▲ +1.19% | $0.3700 (−92.40%) |
Aug 5, 2026 11w ago | 8-K | $12.25 $13.53 | ▲ +10.45% | ▲ +10.10% | $0.3700 (−96.98%) |
Jul 30, 2026 12w ago | 8-K | $12.86 $12.83 | ▼ −0.23% | ▼ −3.86% | $0.3700 (−97.12%) |
Jun 22, 2026 18w ago | 8-K | $13.73 $14.11 | ▲ +2.77% | ▲ +3.22% | $0.3700 (−97.31%) |
Showing 10 of 17
US Market Status
Market Closed — Opens Wed (10h 4m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers